X4 is a clinical-stage biopharmaceutical company focused on the research, development and commercialization of novel therapeutics for the treatment of rare diseases. The Company’s pipeline is comprised of oral, small molecule antagonists of chemokine receptor CXCR4, which have the potential to treat a broad range of rare diseases, including primary immunodeficiencies, or PIs, and certain types of cancer. The Company’s lead product candidate, mavorixafor (X4P-001), is an oral, allosteric antagonist of the CXCR4 receptor designed to correct the abnormal signaling caused by the receptor / ligand interaction and enable mobilization and trafficking of immune cells.